Basal growth hormone concentrations in blood and the risk for prostate cancer: A case-control study

Prostate

Volumn 64, Issue 2, 2005, Pages 109-115

  Fuhrman, Barbara ^a   Barba, Maddalena ^a,b   Schünemann, Holger J ^c   Hurd, Thelma ^a,d   Quattrin, Teresa ^e   Cartagena, Ruben ^a,f   Carruba, Giuseppe ^g   Muti, Paola ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY AT BUFFALO   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e STATE UNIVERSITY OF NEW YORK   (United States)

^f VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^g UNIVERSITY OF PALERMO   (Italy)

Author keywords

Epidemiological studies; Growth hormone; Prostate cancer

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER EPIDEMIOLOGY; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; EDUCATION; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE FEEDBACK; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RACE; SMOKING; STATISTICAL SIGNIFICANCE; WAIST CIRCUMFERENCE;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 20344380164     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20203     Document Type: Article

References (31)

1. Partridge L, Gems D. Mechanisms of aging: Public or private? Nat Rev Genet 2002;3:165-175.
2. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-137.
3. Muller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev 1999;79:511-607.
4. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279:563-566.
5. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-1106.
6. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000;85:4258-4265.
7. Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr, Hsing AW. Insulin-like growth factors and prostate cancer: A population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2001;10:421-427.
8. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115-1118.
9. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D. Serum insulin-like growth factor I: Tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 2003;63:3991-3994.
10. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: A prospective study. J Natl Cancer Inst 2000;92:1910-1917.
11. Lacey JV Jr, Hsing AW, Fillmore CM, Hoffman S, Helzlsouer KJ, Comstock GW. Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study. Cancer Epidemiol Biomarkers Prev 2001;10:1101-1102.
12. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulous D. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 1998;90:911-915.
13. Reiter E, Bonnet P, Sente B, Dombrowicz D, De Leval J, Closset J, Hennen G. Growth hormone and prolactin stimulate androgen receptor. Mol Cell Endocrinol 1992;88:77-87.
14. Reiter E, Kecha O, Hennuy B, Lardinois S, Klug M, Bruyninx M, Closset J, Hennen G. Growth hormone directly affects the function of the different lobes of the rate prostate. Endocrinology 1995;136:3338-3345.
15. Ballesteros M, Leung KC, Ross RJM, Iismaa TP, Ho KKY. Distribution and abundance of messenger ribonucleic acid for growth hormone receptor isoforms in human tissues. J Clin Endocrinol Metab 2000;85:2865-2871.
16. Chopin LK, Veveris-lowe TL, Phillips AF, Herington AC. Coexpression of GH and GHR isoforms in prostate cancer cell lines. Growth Horm IGF Res 2002;12:126-136.
17. Muti P, Westerlind K, Wu T, Grimaldi T, De Berry J 3rd, Schunemann H, Freudenheim JL, Hill H, Carruba G, Bradlow L. Urinary estrogen metabolites and prostate cancer: A case-control study in the United States. Cancer Causes Control 2002;13:947-955.
18. Catalona WJ. Diagnosis, staging, and surgical treatment of prostatic carcinoma. Arch Intern Med 1987;147:361-380.
19. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977;20:680-688.
20. Ferrini L, Steven H Woolf. Screening for prostate cancer in American men. Am J Prev Med 1998.
21. Elmlinger MW, Dengler T, Weinstock C, Kuehnel W. Endocrine alterations in the aging male. Clin Chem Lab Med 2003;41(7): 934-941.
22. Muti P, Gaddi P, Quattrin T. Correspondence re: Chokkalingam A, et al. Insulin-like growth factors and prostate cancer: A population-based case-control study in China. Cancer Epidemiol Biomark Prev 2001;10:421.
23. Cancer Epidemiol Biomark Prev 2002;11:323.
24. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-1396.
25. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J Natl Cancer Inst 1999;91:151-156.
26. Le Marchand L, Donlon T, Seifried A, Keaks R, Rinaldi S, Wilkens L. Association of a common polymorphism in the human GH1 gene with colorectal Neoplasia. J Natl Cancer Inst 2002;94:434-460.
27. Root AW. Regulation of energy balance. Curr Opin Pediatr 2004;16(2):137-138.
28. Italian Association for Research on Brain Aging: Multicenter Study Group. Function of GH/IGF axis in aging: Multicenter study in 152 healthy elderly subjects. Aging (Milano) 1997;9:185-192.
29. Gurlek A, Gedik O. Endogenous sex steroid, GH and IGF-I levels, in normal elderly men: Relationships with bone mineral density and markers of bone turnover. J Endocrinol Invest 2001;24(6): 408-414.
30. Mehta A, Hindmarsh PC. The use of somatropin (recombinant growth hormone) in children of short stature. Pediatric Drugs 2002;4(1):37-47.
31. Modlinska A, Babinska A, Faran G, Sworczak K. Clinical and metabolic effects of recombinant growth hormone in cardiac insufficiency. Przegl Lek 2003;60(5):349-352.